Enfusion (ENFN) Projected to Post Quarterly Earnings on Tuesday

Enfusion (NYSE:ENFN) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $54.39 million for the quarter.

Enfusion (NYSE:ENFN) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The company had revenue of $52.94 million during the quarter, compared to analysts’ expectations of $53.98 million. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Enfusion Price Performance

Shares of ENFN opened at $11.24 on Monday. Enfusion has a 1-year low of $7.83 and a 1-year high of $11.80. The stock has a market cap of $1.44 billion, a PE ratio of 280.95, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. The firm has a fifty day moving average price of $10.98 and a 200 day moving average price of $9.90.

Insider Buying and Selling at Enfusion

In other news, insider Bronwen Bastone sold 3,126 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $35,573.88. Following the transaction, the insider now directly owns 221,875 shares in the company, valued at $2,524,937.50. The trade was a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Neal Pawar sold 2,769 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $31,788.12. Following the transaction, the chief operating officer now owns 1,231,627 shares in the company, valued at $14,139,077.96. The trade was a 0.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 101,789 shares of company stock worth $1,127,449. 36.44% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ENFN shares. Piper Sandler boosted their price target on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research report on Monday, December 23rd. William Blair restated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Stifel Nicolaus lifted their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.